Revvity Bundle
How did Revvity emerge from PerkinElmer’s legacy?
In 2023 PerkinElmer spun off its applied, food, and enterprise services and rebranded the remaining life‑sciences and diagnostics business as Revvity, sharpening focus on precision diagnostics, multi‑omics, and translational research.
Revvity traces roots to Perkin‑Elmer, founded in 1937 in Richmond, California, evolving from analytical instruments into a global life‑sciences and diagnostics pure‑play with over 11,000 employees and a multi‑billion‑dollar revenue run‑rate.
Core offerings now span reagents, instruments, software, and services across genomics, proteomics, imaging, and diagnostics; see Revvity Porter's Five Forces Analysis for competitive context.
What is the Revvity Founding Story?
Founding Story of the Revvity company traces to April 19, 1937, when Richard Perkin and Charles Elmer established Perkin-Elmer in Richmond, California, to build precision optical and analytical instruments for research and industry.
Founding Story
Perkin and Elmer began by crafting custom spectrometers and optical components, serving government and industrial labs; wartime contracts in the 1940s accelerated growth and technical depth.
- Founded on April 19, 1937, in Richmond, California by Richard Perkin and Charles Elmer
- Early product focus: spectrophotometers, infrared instruments and custom optical components
- Bootstrapped growth supplemented by 1940s wartime contracts that expanded manufacturing and R&D
- Evolution through decades of acquisitions led to a life-sciences and diagnostics portfolio, culminating in the 2023 rebrand to Revvity
The original business model targeted government and industrial customers with high-precision instruments; Perkin-Elmer’s name reflected founders’ surnames and a craftsmanship ethos, while reinvested cash flow drove early expansion and capability building.
Across the 20th century the company diversified via acquisitions into life sciences and diagnostics, establishing a product portfolio that by the 2010s included analytical instruments, genomic and diagnostic platforms; strategic deals and restructuring over decades set the stage for a 2023 spin and rebrand to Revvity, aimed at refocusing on health-science solutions.
Key factual milestones in the timeline: founded 1937; wartime contracts in the 1940s that scaled optics production; multi-decade acquisition-driven expansion into life sciences; strategic corporate separation and 2023 rebrand to Revvity to reflect renewed focus and velocity in health markets.
For more on strategic rationale and corporate moves that shaped the change, see Growth Strategy of Revvity.
Revvity SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Revvity?
From mid-20th-century instrumentation to a focused life-sciences leader, Revvity's early growth and expansion trace a shift from spectrometry and chromatography dominance to genomics-era reagents, imaging, and diagnostics.
Roots in Analytical Instruments
From the 1940s–1970s, Perkin-Elmer earned adoption across chemical, aerospace, and government labs through spectrometry and chromatography platforms, securing defense and NASA-era optics contracts that laid the foundation for later life-sciences investments.
Pivot toward Life Sciences
The 1990s–2000s saw accelerated moves into reagents, detection, and imaging to support genomics and proteomics during the Human Genome Project; acquisitions built capabilities in sequencing prep, detection chemistry, and high-resolution imaging.
Strategic Acquisitions
In 2011 Perkin-Elmer acquired Caliper Life Sciences for approximately $600 million, adding microfluidics, in vivo imaging, and high-content screening—platforms critical to pharmaceutical discovery and automation.
Diagnostics and Global Scale-Up
During the 2010s the company expanded newborn screening and infectious-disease diagnostics, scaling manufacturing across the US, Europe, and Asia and establishing a robust precision-diagnostics product portfolio.
In 2022 Perkin-Elmer sold its Applied, Food, and Enterprise Services businesses to New Mountain Capital for approximately $2.45 billion, setting the stage for the May 16, 2023 rebrand to Revvity and a focused push into multi-omics, cell and gene therapy tools, and precision diagnostics.
Post-rebrand Strategy
Post-rebrand Revvity emphasized NGS library prep kits, automated sample-prep systems, and cell and gene therapy workflows, targeting mid-single to high-single-digit organic growth and margin expansion through portfolio mix and operational efficiencies.
Market Positioning and Reception
Analysts recognized a cleaner company narrative versus diversified peers, noting the Revvity company history and Revvity history timeline as a decisive spin-off origin that sharpened focus on higher-growth, higher-margin markets; management set mid-to-high single-digit organic targets.
For related corporate background and values see Mission, Vision & Core Values of Revvity
Revvity PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Revvity history?
Milestones, Innovations and Challenges of the Revvity company history trace a focused transformation from a diversified life‑science legacy into a software‑enabled reagents and instruments leader, anchored by newborn screening reach, genomics enablement, COVID‑era diagnostics scale and a 2022–2023 portfolio reshaping toward recurring reagent revenue and AI‑driven workflows.
| Year | Milestone |
|---|---|
| 2021 | Legacy business rapidly scaled SARS‑CoV‑2 PCR kits and automation, contributing a temporary revenue surge during the pandemic. |
| 2022 | Company separation and rebrand to concentrate life‑sciences and diagnostics operations and pursue a focused growth strategy. |
| 2023 | Investment in cloud‑enabled informatics, AI image analysis, and expansion of NGS library prep and automation toolkits to serve oncology and infectious disease workflows. |
Revvity advanced time‑resolved fluorescence, luminescence detection, high‑content screening and in vivo imaging platforms that enabled high‑throughput screening and translational biology. Its newborn screening reagents and instruments claimed screening reach to millions of infants annually and a growing recurring reagent franchise across oncology, liquid biopsy and infectious disease.
Time‑resolved detection
Advanced fluorescence and luminescence systems improved signal‑to‑noise for HTS and assay miniaturization.
High‑content screening
Integrated imaging optics with AI analysis increased throughput for phenotypic drug discovery pipelines.
NGS library prep & automation
Built comprehensive NGS consumables and automation toolkits and partnered with sequencer vendors for end‑to‑end workflows.
Newborn screening leadership
Reagents and instruments supported screening programs that reach an estimated millions of infants worldwide annually.
COVID‑19 diagnostics
Rapid development of SARS‑CoV‑2 PCR kits and lab automation generated a significant but transient revenue uplift during 2020–2021.
AI & cloud informatics
Investments in software and AI-driven image analysis aimed to convert instrument sales into recurring software and reagent revenue.
Revvity faced intense competition from Thermo Fisher, Danaher/Cytiva and Agilent across reagents and instruments, plus pricing sensitivity in academic markets and macro headwinds in China during 2023–2024. Management prioritized operating discipline, channel focus on biopharma, and innovation in multiplexed assays and workflow automation to counter the unwind of COVID testing revenue.
Competitive intensity
Market share battles with larger life‑science conglomerates pressured pricing and margin in core reagent franchises; Revvity responded with targeted product differentiation and channel specialization.
Post‑COVID normalization
Declining COVID testing volumes in 2022–2023 created a revenue headwind, prompting cost realignments and strategic prioritization of recurring revenue streams.
China macro risks
Slower growth and regulatory variability in China during 2023–2024 affected regional sales; management increased focus on diversified geographies and biopharma partnerships.
Reagent recurring revenue
Shift toward consumables and software aimed to boost recurring margins and reduce capital equipment cyclicality.
Partnerships & patents
Collaborations with top‑20 pharmas, academic centers and public health agencies, plus numerous patents, strengthened assay standardization and market credibility.
Strategic focus
Portfolio reshaping and capital allocation emphasized cell and gene therapy, oncology diagnostics and population screening as long‑term growth drivers.
For additional context on revenue models, see Revenue Streams & Business Model of Revvity.
Revvity Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Revvity?
Timeline and Future Outlook of Revvity traces its roots from Perkin-Elmer in 1937 through a strategic spin-off and 2023 rebrand, with a focus on genomics, proteomics, imaging, diagnostics, recurring revenues, and automation to capture growth across life-sciences tools and diagnostics markets.
| Year | Key Event |
|---|---|
| 1937 | Perkin-Elmer founded in Richmond, California to produce precision optical and analytical instruments. |
| 1940s–1960s | Expanded via government and aerospace contracts; advanced optical systems and spectroscopy. |
| 1970s–1990s | Diversified into analytical chemistry and life sciences and built a global sales network across North America and Europe. |
| 2011 | Acquired Caliper Life Sciences for approximately $600M, adding microfluidics, in vivo imaging, and high-content screening. |
| 2017–2019 | Strengthened diagnostics and reagents franchises, investing in newborn screening and infectious disease testing infrastructure. |
| 2020–2021 | Scaled COVID-19 PCR and automation solutions, driving a significant testing revenue surge and installed base growth. |
| 2022 | Announced divestiture of Applied, Food, and Enterprise Services to New Mountain Capital for about $2.45B, enabling a pure-play life sciences/diagnostics entity. |
| May 16, 2023 | Rebranded and relaunched as Revvity, focused on genomics, proteomics, imaging, and diagnostics solutions. |
| 2023–2024 | Emphasized NGS library prep, automated sample prep, multiplexed detection, and AI-enabled imaging with cost realignment after COVID normalization and China softness. |
| 2024 | Integrated cloud informatics and workflow automation targeting mid- to high-single-digit organic growth and margin expansion. |
| 2025 | Focused strategically on end-to-end multi-omics workflows for oncology, rare disease, and cell/gene therapy with selective M&A for reagents and software. |
Strategic growth priorities
Revvity targets higher recurring revenue via reagents and software, aiming to expand clinical genomics and population screening, including newborn and prenatal programs.
Automation and informatics investment
Management prioritizes automation, cloud informatics, and AI-enabled imaging to reduce time-to-answer and cost-per-sample while improving lab productivity.
Market and revenue outlook
With the global life-sciences tools market projected to exceed $100B by 2025 and diagnostics above $90B, Revvity aims for mid- to high-single-digit organic growth and margin expansion through product mix shift.
M&A and partnerships
Selective acquisitions are planned to add specialty reagents and software; deeper biopharma partnerships will support translational research and multi-omics workflows.
Revvity Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Revvity Company?
- What is Growth Strategy and Future Prospects of Revvity Company?
- How Does Revvity Company Work?
- What is Sales and Marketing Strategy of Revvity Company?
- What are Mission Vision & Core Values of Revvity Company?
- Who Owns Revvity Company?
- What is Customer Demographics and Target Market of Revvity Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.